Microbiome Therapeutics Market

Microbiome Therapeutics Market Size, Share, Growth & Forecast Analysis, By Type (FMT, and Microbiome Drugs), By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, and Diabetes), & By Region –Global Market Insights 2022 to 2032

Microbiome Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Microbiome Therapeutics Market Outlook (2022-2032)

The microbiome therapeutics market size is estimated at US$ 112.20 Million in 2022 and is anticipated to grow at a CAGR of 32% from 2022 to 2032. The microbiome therapeutics market size is anticipated to reach US$ 1801.91 Million in 2032.

The market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapeutics. The market for microbiome therapeutics was severely harmed by the COVID-19 pandemic. Globally, clinical trial research has been severely disrupted. The demand for microbiome therapeutics is rising as target diseases are becoming more prevalent.

The development of microbiome research is anticipated to aid in the search for more effective cures for infections and other diseases, improving the results of medical treatment. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a larger portion of the population, and some countries' governing bodies are changing their strategies to support the adoption of microbiome-based treatments. Market vendors now have profitable growth opportunities to increase their market share.

The high cost of microbiome therapeutics and strict regulatory guidelines resulting from the product's complexity are the two main factors limiting the market growth. The overall cost of the product is increased by high development, production, and regulatory costs, which have an impact on treatment costs.

Report Attributes

Details

Microbiome Therapeutics Market Size (2022)

US$ 112.20 Million

Projected Microbiome Therapeutics Market Value (2033)

US$ 1801.91 Million

Global Microbiome Therapeutics Market Growth Rate (2022-2032)

32%

North America Microbiome Therapeutics Market Share 2022-2032)

74%

Clostridium difficileinfection Microbiome Therapeutics Market Share

33%

Key Companies Profiled

  • OpenBiome
  • Seres Therapeutics Inc.
  • 4D Pharma plc.
  • Locus Biosciences, Inc.
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Intralytix, Inc.
  • Microbiotica
  • Second Genome
  • Rebiotix Inc.
  • Vedanta Bioscience, Inc.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Improved Microbiome Sequencing Capabilities are Likely to Boost the Microbiome Therapeutics Market

The main factor anticipated to fuel the growth of the global microbiome therapeutics market is the results of the Human Microbiome Project and other large-scale studies of human bacterial symbioses, which have attracted enormous attention from applied biomedical research organizations. When compared to the Human Microbiome Project (HMP), which identified 60 million genes, 600 microbial reference genomes, and 700 metagenomes, the MetaHIT catalog contains 3.3 million non-redundant human microbiome genes in nearly every set of genes for the human gut microbiome.

The application of therapeutics to the study of the microbiome is made possible by all of this data. Improved microbiome sequencing capabilities are another important factor anticipated to accelerate the growth of the global market for microbiome therapeutics. As a result, it is anticipated that basic research in microbiome sequencing is anticipated to advance and further reveal the diversity of the microbiome, allowing for the development of novel or enhanced microbiome therapeutics.

R&D Initiatives Have Accelerated

R&D efforts started to pick up again as a result of the easing of government restrictions brought on by the epidemic and the introduction of virtual clinical trials. The growing relationship between Big Pharma and microbiome therapies A recent wave of partnerships in this field included Big Pharma as a participant. Big Pharma became more cautious following a number of high-profile failures in clinical trials.

As a result of the decline in the number of significant microbes, dangerous infectious diseases and organisms such as Clostridium difficile and ulcerative colitis have become more prevalent. This has boosted the microbiome therapeutics market trends along with the microbiome therapeutics market adoption trends.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Increasing Production Expenses and Regulatory Burdens are Hurdles

The need for final products with high safety standards that are of clinical grade and that have undergone extensive polishing has led to the adoption of extremely sophisticated methods. The companies in the microbiome industry are anticipated to need to make significant investments in the initial set of production units for such cutting-edge technological methods.

The strict regulatory requirements for sanctioning any new development related to the biopharmaceutical sector have been the main obstacle to the quick development of microbiome therapeutics for various targeted diseases. The development of the global market for microbiome therapeutics is constrained by the incomplete understanding of microbiomes and the testing and approval of therapeutics based on human microbiomes.

Analysis of Segmentation

Which Market Application Segment Is Gaining A Foothold?

The application segment for C. difficile infection is anticipated to contribute the highest share of 33% by 2032. This high microbiome therapeutics market share is thought to be the result of more and earlier launches of C. difficile microbiome therapeutics. The growing use of fecal microbiota transplants (FMT) in the management of C is responsible for the expansion of the microbiome therapeutics market segment.

GI disorders (Crohn's disease, inflammatory bowel diseases, ulcerative colitis), prevention of preterm birth, immuno-oncology, and rare metabolic disorders like phenylketonuria, urea cycle disorders, lactose intolerance, glioblastoma, etc., are some of the other application for which active microbiome therapeutics clinical trials are ongoing.

Due to increased attention being paid to changes in gut microbial composition in Crohn's disease patients, the Crohn's disease application segment of the microbiome therapeutics market is predicted to grow profitably over the course of the forecast period. For instance, according to the Microbiome Journal in 2020, fecal microbiota transplantation can be used to keep patients with Crohn's disease in remission.

Which Market Type Segment is Making Headway?

In the forecast period, faecal microbiota therapy (FMT) held a sizable share of the microbiome therapeutics market. The widespread use of the segment in the management of C. difficile infection is credited with its dominance. Additionally, it is anticipated that the microbiome therapeutics market introduction of capsules and increased R&D concentrating on developments to discover additional therapeutic applications of FMT are anticipated to fuel the microbiome therapeutics market growth.

Due to a strong pipeline and the creation of cutting-edge and novel medications, microbiome drugs are predicted to grow at the fastest rate over the forecast period. Most drugs are still in the early stages of development.

Country Insights

What Should be Expected From The North American Market For Microbiome Therapeutics?

By having the largest microbiome therapeutics market share of 74% for the forecast period, North America dominated the microbiome therapeutics market. The region's dominance is primarily attributed to its well-established research facilities for the creation of novel microbiome therapeutics and its growing target population.

United States

In the global market for microbiome therapeutics, the United States is anticipated to hold the largest market share, exceeding 44%. The United States market for microbiome therapeutics is anticipated to grow as a result of new medications' early release and quick uptake.

In addition, the prevalence of initiatives like the Canadian Microbiome Initiative (CMI) in Canada encourages interaction between partners and stakeholders. Because of this, research can now be concentrated on the creation of microbiome therapeutics.

What are the Microbiome Therapeutics Market Possibilities in Europe?

During the forecast period, Europe is anticipated to show significant growth. In Europe, Germany is a developing market for microbiome therapeutics. Even though microbiome therapeutics are expensive, favorable reimbursement policies are anticipated to make treatment uptake easier in the coming years. Startups are also receiving funding for microbiome-based product development and research.

What Market Opportunities Exist For Microbiome Therapeutics in Japan?

Through the forecast period, Japan is expected to take the lead in the adoption of microbiome therapeutics in the Asia Pacific region. Researchers from Japan are trying to create new products that are anticipated to replicate the beneficial aspects of their microbiota by using the findings of studies on the country's centenarians.

The collaboration aims to overcome some of the biggest technological barriers to furthering stem cell research. The US$ 2.3 million funds were given to Cykinso (Tokyo), who used them to create and market a test kit for intestinal flora called Mykinso. The company intends to use the money for business development activities, which is anticipated to involve creating a system for providing nutritional advice using the information obtained from the intestinal flora tests.

Therefore, it is likely that government investments and initiatives are anticipated to spur microbiome therapeutics market growth during the forecast period.

Comparative View of Adjacent Microbiome Therapeutics Market

Microbiome Therapeutics Market :

Attributes

Microbiome Therapeutics Market

CAGR

(2022-2032)

32%

Market Value

(2027)

USD 449.64 Million

Growth Factor

The microbiome therapeutics market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapeutics.

Opportunity

The demand for microbiome therapeutics is rising as target diseases are becoming more prevalent.

Key Trends

These developments are currently in the clinical stage, and it is anticipated that they will soon have a favourable effect on the expansion of the global microbiome therapeutics market.

Skin Microbiome Modulators Market :

Attributes

Skin Microbiome Modulators Market

CAGR

(2022-2032)

16%

Market Value

(2027)

USD 1773.95 Million

Growth Factor

A Growing Focus on the Health Benefits of the Microbiome

Opportunity

Next-Generation Probiotics Investment for Probiotic Drug Enhancement

Key Trends

More established cosmetic companies are entering the market for skin microbiome regulators.

Neurostimulation Devices Market :

Attributes

Neurostimulation Devices Market

CAGR

(2022-2032)

12.8%

Market Value

(2027)

USD 9.27 Billion

Growth Factor

The demand for neurostimulation devices is anticipated to increase in the near future due to the rising incidence of neurological diseases.

Opportunity

Implanting a neurostimulation device is a minimally invasive procedure, and the market is anticipated to see new growth opportunities as a result of the growing demand for such surgeries due to shorter hospital stays and quicker recovery.

Key Trends

In order to develop cutting-edge products and technologies, like implantable neurostimulation devices, manufacturers are spending more on research and development (R&D).

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Competitive Landscape

The majority of microbiome therapeutics market participants in the microbiome therapeutics space collaborate and partner with well-known pharmaceutical companies and academic institutions. Small start-up and clinical-stage microbiome companies are utilizing venture capital to introduce novel therapeutics based on the microbiome to the global microbiome therapeutics market.

Despite a decline in overall venture capital investments, the microbiome sector saw high VC investments in 2016, raising roughly US$ 336 million. Another significant trend in the market for global microbiome therapeutics is partnerships and research collaborations.

Recent Development :

Date

Company Name

Strategy

Details

January 2022

Hudson Institute and BiomeBank

Agreement

An agreement for a 4-year partnership between Hudson Institute and BiomeBank and BiomeBank for the development and discovery of microbial therapies was signed in January 2022.

February 2022

AOBiome Therapeutics

Research

AOBiome Therapeutics, a clinical-stage biotech company working to develop topical biologic treatments for conditions characterised by systemic inflammation, reported encouraging pivotal Phase 2b results from its trial evaluating B244, the product's topical and intranasal formulation, in pruritus (itch) and the onset of atopic dermatitis in February 2022. (eczema).

2020

4D Pharma

Merger

2020 is anticipated to mark 4D Pharma's transition to NASDAQ public company status after it merged with Longevity Acquisition Corporation. The agreement with Longevity is anticipated to enable support for and advancement of the Live Biotherapeutic created by 4D Pharma. The FDA classifies biological products containing a live organism that are used in the diagnosis, treatment, or prevention of disease as live biotherapeutics.

Early 2022

Nahdi Medical Co. and OptiBiotix Health Plc.

Agreement

An exclusive sales and distribution agreement between Nahdi Medical Co. and OptiBiotix Health Plc. was signed in 2022 and is anticipated to go into effect in 2023. As part of a new agreement with Nahdi, the company's GoFigure and SlimBiome Medical weight management solutions is anticipated to be available in the Kingdom of Saudi Arabia starting in early 2022. This is anticipated to help in the fight against the obesity pandemic.

July 2021

Biocodex Microbiota Foundation

Proposal

The Biocodex Microbiota Foundation published a request for proposals in July 2021 for microbiome research grants totaling more than USD 26,000 in Canada. These grants are anticipated to stimulate new market developments.

December 2021

Kaleido Biosciences and Janssen

Partnership

Kaleido Biosciences and Janssen announced a partnership in December 2021 to explore the potential of microbiome metabolic therapies for the treatment of immune, atopic, and metabolic conditions that first appear in childhood.

Key Segments of Microbiome Therapeutics Industry Research

  • By Type :

    • FMT
    • Microbiome Drugs
  • By Application :

    • C. difficile
    • Crohn's Disease
    • Inflammatory Bowel Disease
    • Diabetes
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Type , 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type , 2022-2032

        5.3.1. FMT

        5.3.2. Microbiome Drugs

    5.4. Y-o-Y Growth Trend Analysis By Type , 2017-2021

    5.5. Absolute $ Opportunity Analysis By Type , 2022-2032

6. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Application , 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application , 2022-2032

        6.3.1. C. difficle

        6.3.2. Crohn's disease

        6.3.3. Inflammatory Bowel Disease

        6.3.4. Diabetes

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Application , 2017-2021

    6.5. Absolute $ Opportunity Analysis By Application , 2022-2032

7. Global Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Type

        8.2.3. By Application

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Type

        8.3.3. By Application

    8.4. Key Takeaways

9. Latin America Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Type

        9.2.3. By Application

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Application

    9.4. Key Takeaways

10. Europe Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Type

        10.2.3. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Application

    10.4. Key Takeaways

11. South Asia Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Type

        11.2.3. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Application

    11.4. Key Takeaways

12. East Asia Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Type

        12.2.3. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Application

    12.4. Key Takeaways

13. Oceania Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Type

        13.2.3. By Application

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Application

    13.4. Key Takeaways

14. MEA Microbiome Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Type

        14.2.3. By Application

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Application

    14.4. Key Takeaways

15. Key Countries Microbiome Therapeutics Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2021

            15.1.2.1. By Type

            15.1.2.2. By Application

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2021

            15.2.2.1. By Type

            15.2.2.2. By Application

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2021

            15.3.2.1. By Type

            15.3.2.2. By Application

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2021

            15.4.2.1. By Type

            15.4.2.2. By Application

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2021

            15.5.2.1. By Type

            15.5.2.2. By Application

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2021

            15.6.2.1. By Type

            15.6.2.2. By Application

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2021

            15.7.2.1. By Type

            15.7.2.2. By Application

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2021

            15.8.2.1. By Type

            15.8.2.2. By Application

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2021

            15.9.2.1. By Type

            15.9.2.2. By Application

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2021

            15.10.2.1. By Type

            15.10.2.2. By Application

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2021

            15.11.2.1. By Type

            15.11.2.2. By Application

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2021

            15.12.2.1. By Type

            15.12.2.2. By Application

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2021

            15.13.2.1. By Type

            15.13.2.2. By Application

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2021

            15.14.2.1. By Type

            15.14.2.2. By Application

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2021

            15.15.2.1. By Type

            15.15.2.2. By Application

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2021

            15.16.2.1. By Type

            15.16.2.2. By Application

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2021

            15.17.2.1. By Type

            15.17.2.2. By Application

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2021

            15.18.2.1. By Type

            15.18.2.2. By Application

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2021

            15.19.2.1. By Type

            15.19.2.2. By Application

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2021

            15.20.2.1. By Type

            15.20.2.2. By Application

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2021

            15.21.2.1. By Type

            15.21.2.2. By Application

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Type

        16.3.3. By Application

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. OpenBiome

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Seres Therapeutics Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. 4D Pharma plc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Locus Biosciences, Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Enterome SA

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Finch Therapeutics Group, Inc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Intralytix, Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Microbiotica

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Second Genome

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Rebiotix Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Vedanta Bioscience, Inc.

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Microbiome Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 02: Global Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 03: Global Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 04: North America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 05: North America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 06: North America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 07: Latin America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 08: Latin America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 09: Latin America Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 10: Europe Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 11: Europe Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 12: Europe Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 13: South Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: South Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 15: South Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 16: East Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: East Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 18: East Asia Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 19: Oceania Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 20: Oceania Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 21: Oceania Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

Table 22: MEA Microbiome Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 23: MEA Microbiome Therapeutics Market Value (US$ Mn) Forecast by Type , 2017-2032

Table 24: MEA Microbiome Therapeutics Market Value (US$ Mn) Forecast by Application , 2017-2032

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 02: Global Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 03: Global Microbiome Therapeutics Market Value (US$ Mn) by Region, 2022-2032

Figure 04: Global Microbiome Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 05: Global Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 06: Global Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 07: Global Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 08: Global Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 09: Global Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 10: Global Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 11: Global Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 12: Global Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 13: Global Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 14: Global Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 15: Global Microbiome Therapeutics Market Attractiveness by Region, 2022-2032

Figure 16: North America Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 17: North America Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 18: North America Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 20: North America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 23: North America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 24: North America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 25: North America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 26: North America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 27: North America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 28: North America Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 29: North America Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 30: North America Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 32: Latin America Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 33: Latin America Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 35: Latin America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 38: Latin America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 39: Latin America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 40: Latin America Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 41: Latin America Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 42: Latin America Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 43: Latin America Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 44: Latin America Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 45: Latin America Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 46: Europe Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 47: Europe Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 48: Europe Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 50: Europe Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 53: Europe Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 54: Europe Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 55: Europe Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 56: Europe Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 57: Europe Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 58: Europe Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 59: Europe Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 60: Europe Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 61: South Asia Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 62: South Asia Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 63: South Asia Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 64: South Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 65: South Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: South Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: South Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 68: South Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 69: South Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 70: South Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 71: South Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 72: South Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 73: South Asia Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 74: South Asia Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 75: South Asia Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 76: East Asia Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 77: East Asia Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 78: East Asia Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 79: East Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 80: East Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: East Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: East Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 83: East Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 84: East Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 85: East Asia Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 86: East Asia Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 87: East Asia Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 88: East Asia Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 89: East Asia Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 90: East Asia Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 91: Oceania Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 92: Oceania Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 93: Oceania Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 94: Oceania Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 95: Oceania Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 96: Oceania Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 97: Oceania Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 98: Oceania Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 99: Oceania Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 100: Oceania Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 101: Oceania Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 102: Oceania Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 103: Oceania Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 104: Oceania Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 105: Oceania Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Figure 106: MEA Microbiome Therapeutics Market Value (US$ Mn) by Type , 2022-2032

Figure 107: MEA Microbiome Therapeutics Market Value (US$ Mn) by Application , 2022-2032

Figure 108: MEA Microbiome Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 109: MEA Microbiome Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 110: MEA Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 111: MEA Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 112: MEA Microbiome Therapeutics Market Value (US$ Mn) Analysis by Type , 2017-2032

Figure 113: MEA Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Type , 2022-2032

Figure 114: MEA Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Type , 2022-2032

Figure 115: MEA Microbiome Therapeutics Market Value (US$ Mn) Analysis by Application , 2017-2032

Figure 116: MEA Microbiome Therapeutics Market Value Share (%) and BPS Analysis by Application , 2022-2032

Figure 117: MEA Microbiome Therapeutics Market Y-o-Y Growth (%) Projections by Application , 2022-2032

Figure 118: MEA Microbiome Therapeutics Market Attractiveness by Type , 2022-2032

Figure 119: MEA Microbiome Therapeutics Market Attractiveness by Application , 2022-2032

Figure 120: MEA Microbiome Therapeutics Market Attractiveness by Country, 2022-2032

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

How is the Microbiome Therapeutics Market Growing?

The microbiome therapeutics market is predicted to grow at CAGR of 32% through 2032.

Which Region Holds the Highest Revenue Potential in the Microbiome Therapeutics Market?

North American microbiome therapeutics market holds the highest revenue potential with a market share of 74%.

What is the Future Scope of Growth for the Microbiome Therapeutics Market?

The microbiome therapeutics market is expected to surpass US$ 1801.91 Million by 2032.

What is the Current Microbiome Therapeutics Market Size?

The microbiome therapeutics market size is anticipated to be over US$ 112.20 Million in 2022.

Microbiome Therapeutics Market

Schedule a Call